Platelet‑derived growth factor‑beta as a new marker of deep venous thrombosis

Background: Deep venous thrombosis (DVT) is associated with significant morbidity and mortality. Thus, there is a great need to demonstrate a more efficient biomarker that would confirm the diagnosis of DVT. Our work aimed to evaluate the role of platelet‑derived growth factor‑beta (PDGF‑B) as a new marker of DVT and its correlation with other radiological and laboratory tools used for the diagnosis. Materials and Methods: A case–control study enrolled forty patients selected from our university hospital between April 2018 and August 2018, who divided into two groups: Group I (n = 20) consisted of patients diagnosed with acute venous thrombosis and Group II (n = 20) consisted of patients diagnosed with chronic venous thrombosis. Twenty samples were collected from age‑ and gender‑matched apparently healthy controls to be used as a control. Venous duplex ultrasonography, routine laboratory investigations, D‑dimer (DD), and protein expression of PDGF‑B were performed on all patients. Results: There was a highly significant increase in a protein expression of PDFG‑B in all cases of acute and chronic venous thrombosis compared to the control group with P < 0.001; furthermore, it was more specific than DD for the detection of DVT (specificity 95% and 90%, respectively). Conclusion: Our study submits a novel association of PDGF‑B plasma levels with DVT, and PDGF‑B is considered to be a more specific indicator for DVT than is DD.